uniQure Reports 48-Month AMT-130 Data in Huntington’s Disease
LEXINGTON, Mass. and AMSTERDAM September 29, 2026 — uniQure N.V. announced additional data from ongoing Phase 1/2 studies of...
Phase 2
Advertisement
Cellectar Reports Iopofosine I 131 Data in BTKi-Refractory Waldenström Macroglobulinemia
FLORHAM PARK, N.J. — September 29, 2026 Cellectar Biosciences announced that a subset analysis from the Phase 2 CLOVER-WaM...
Verastem Reports Two-Year RAMP 201 Data in LGSOC
BOSTON — September 28, 2026 Verastem Oncology announced the publication in Gynecologic Oncology of two-year follow-up data from the...
CervoMed Advances Neflamapimod With New Tablet and FDA Dose Flexibility
BOSTON — September 28, 2026 CervoMed Inc. announced pharmacokinetic, regulatory and manufacturing advances for neflamapimod, including a new 50...
MediciNova Reports Phase 2 MN-001 Results in Metabolic Disease
LA JOLLA, Calif. — September 28, 2026 MediciNova, Inc. reported topline results from the randomized, double-blind, placebo-controlled MN-001-NATG-202 Phase...
Advertisements
Acadia Reports Phase 2 RADIANT Results for Remlifanserin
SAN DIEGO — September 25, 2026 Acadia Pharmaceuticals Inc. announced topline Phase 2 results from the RADIANT clinical trial...
Verastem to Present RAMP 201 Biomarker Data at IGCS 2026
BOSTON — September 24, 2026 Verastem Oncology announced that molecular profiling and tumor biomarker findings from the Phase 2...
Annexon to Present Vonaprument Data From ARCHER II
BRISBANE, Calif. — September 24, 2026 Annexon, Inc. announced that it will present two oral presentations on vonaprument at...
AC Immune Reports Positive Week-100 VacSYn Phase 2 Data
LAUSANNE, Switzerland — September 23, 2026 AC Immune SA reported positive safety and immunogenicity results through Week 100 from...
Artelo Files Patent for ART27.13 in Obesity
SOLANA BEACH, Calif. — September 23, 2026 Artelo Biosciences announced that it has filed a new provisional patent application...
Advertisement
